Postmarketing Use of Enfuvirtide in Veterans: Provider Compliance with Criteria for Use,Overall Efficacy,and Tolerability

Abstract

Spanish

French

Background:

Most enfuvirtide outcomes data come from controlled trials of limited duration rather than from routine experience. Because of its uniqueness, the Veterans Health Administration (VHA) implemented specific enfuvirtide prescribing and follow-up criteria (criteria for use; CFU) and then assessed providers' compliance with these criteria and outcomes.

Objective:

To report routine medical care experience with the prescribing. efficacy, and tolerability of enfuvirtide in a nonselective group of treatment-experienced, older, HIV-infected veterans.

Methods:

Veterans receiving at least one outpatient prescription for enfuvirtide between April 2003 and July 2005 were identified from the VHA's HIV Clinical Case Registry (CCR:HIV). Targeted retrospective chart extraction was completed to address inclusion/exclusion criteria and to evaluate patients' continued use, adherence, and tolerance. CCR:HIV data were used for determination of demographics, prescription records, and laboratory results. The final cohort was used to assess providers' compliance with VHA's CFU for enfuvirtide.

Results:

Of 275 evaluable subjects, between 52% and 93% who were prescribed enfuvirtide met each VHA CFU. Median change in CD4 cells and viral load from baseline to 6 months was +39 cells/mm³ and –0.79 log₁₀ (p < 0.001) and at 2 years was +72 cells/mm³ and –1.57 log₁₀ (p < 0.001); 41% and 55% of veterans achieved viral load less than 400 copies/mL at 6 months and 2 years, respectively. Seventy percent of veterans experienced injection site reactions (11% were treatment-limiting). New or worsening adverse effects occurred in 56% of veterans: 32% gastrointestinal, 19% musculoskeletal, and 10% respiratory. Seventy percent of veterans discontinued enfuvirtide within 2 years; the largest portion (12%) stopped treatment within the first month. Documented reasons for discontinuation included patient request (42%), suboptimal response/progression (24%), toxicity (18%), death (13%), and transfer of care outside of the VHA (3%).

Conclusions:

In this treatment-experienced veteran cohort, providers prescribed enfuvirtide in accordance with most CFU, and favorable treatment responses were sustained in patients able to remain on therapy. Challenges that providers and patients face include ongoing education and support for successful long-term use.

Keywords

compliance enfuvirtide HIV outcome

Get full access to this article

View all access options for this article.

References

Product information. Fuzeon (enfuvirtide) for Injection. Nutley, NJ: Roche Laboratories, Inc. and Trimeris Inc., January 2007.

Lalezari

, Henry

, O'hearn

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175–85.

Lazzarin

, Clotet

, Cooper

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186–95.

Nelson

, Arasteh

, Clotet

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40: 404–12.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008: 1–128. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescent-GL.pdf (accessed 2008 Feb 17).

Gathe

, Cooper

, Farthing

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43: 1337–46.

Cahn

, Villacian

, Lazzarin

Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43: 1347–56.

Clotet

, Bellos

, Molina

Efficacy and safety of darunavir–ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169–78.

Food and Drug Administration. Antiviral Drugs Advisory Committee Briefing Document. Maraviroc Tablets NDA 22–128. April 24, 2007. www.fda.gov/ohrms/dockets/ac/cder07.htm#AntiviralDrugs (accessed 2008 Feb 22).

10.

Cooper

, Gatell

, Rockstroh

48-Week results from BENCHMRK-1, a phase 3 study of raltegravir in patients failing ART with triple-class resistant HIV-1 (abstract 788). In: Programs and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3–6, 2008.

11.

Steigbigel

, Kumar

, Eron

48-Week results of BENCHMRK-2, a phase 3 study of raltegravir in patients failing ART with triple-class resistant HIV-1 (abstract 789). In: Programs and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3–6, 2008.

12.

Cahn

, Haurich

, Leider

Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine) versus placebo in treatment-experienced HIV-1 infected patients (abstract H-717). In: Programs and Abstracts of the 47th International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 17–20, 2007.

13.

Raffi

, Katlama

, Saag

Week 12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 Versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006; 42: 870–77.

14.

Trottier

, Walmsley

, Reynes

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1–infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005; 40: 413–21.

15.

Lalezari

, Eron

, Carlson

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17: 691–8.

16.

Witek

, Rockstroh

, Donatacci

Adherence to enfuvirtide and to background antiretroviral therapy over 48 weeks and its impact on treatment efficacy (abstract We PeB5822). In: Program and Abstracts of the 15th International AIDS Conference. Bangkok, Thailand, July 11–16, 2004.

17.

Cohen

, Dusek

, Green

, Johns

, Nelson

, Recny

. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 2002; 16: 327–35.

18.

Jamjian

, McNicholl

. Enfuvirtide; first fusion inhibitor for treatment of HIV infection. Am J Health Syst Pharm 2004; 61: 1242–7.

19.

Clotet

, Raffi

, Cooper

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18: 1137–46.